You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameProtriptyline
Accession NumberDB00344  (APRD00441)
TypeSmall Molecule
GroupsApproved
DescriptionProtriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.
Structure
Thumb
Synonyms
3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine
3-(5H-Dibenzo[a,D]cyclohepten-5-yl)-N-methyl-1-propanamine
5-(3-Methylaminopropyl)-5H-dibenzo[a,D]cycloheptene
7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
Amimetilina
N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propanamine
N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propylamine
Protriptilina
Protriptylin
Protriptyline
Protriptylinum
External Identifiers
  • MK 240
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Triptil Tab 10mgtablet10 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1966-12-312001-01-25Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Protriptyline Hydrochloridetablet, film coated10 mg/1oralRising Pharmaceuticals, Inc2010-06-11Not applicableUs
Protriptyline Hydrochloridetablet5 mg/1oralRoxane Laboratories, Inc2008-09-16Not applicableUs
Protriptyline Hydrochloridetablet, film coated5 mg/1oralHi Tech Pharmacal Co., Inc.2013-10-28Not applicableUs
Protriptyline Hydrochloridetablet10 mg/1oralRoxane Laboratories, Inc2008-09-16Not applicableUs
Protriptyline Hydrochloridetablet, film coated10 mg/1oralHi Tech Pharmacal Co., Inc.2013-10-28Not applicableUs
Protriptyline Hydrochloridetablet, film coated5 mg/1oralEpic Pharma, LLC2013-01-09Not applicableUs
Protriptyline Hydrochloridetablet, film coated5 mg/1oralRising Pharmaceuticals, Inc2010-06-11Not applicableUs
Protriptyline Hydrochloridetablet, film coated10 mg/1oralEpic Pharma, LLC2013-01-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
TriptilNot Available
VivactilOdyssey
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Protriptyline hydrochloride
ThumbNot applicableDBSALT001192
Categories
UNII4NDU154T12
CAS number438-60-8
WeightAverage: 263.3767
Monoisotopic: 263.167399677
Chemical FormulaC19H21N
InChI KeyInChIKey=BWPIARFWQZKAIA-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
IUPAC Name
methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)amine
SMILES
CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression.
PharmacodynamicsProtriptyline is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the reuptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for approximately two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: α1 and β1 receptors are sensitized, α2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.
Mechanism of actionProtriptyline acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationCumulative urinary excretion during 16 days accounted for approximately 50% of the drug. The fecal route of excretion did not seem to be important.
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects include anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal discomfort, sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9862
Caco-2 permeable+0.7821
P-glycoprotein substrateSubstrate0.7406
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.5597
Renal organic cation transporterInhibitor0.6622
CYP450 2C9 substrateNon-substrate0.7206
CYP450 2D6 substrateSubstrate0.9034
CYP450 3A4 substrateSubstrate0.5285
CYP450 1A2 substrateNon-inhibitor0.7595
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.641
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7512
Ames testNon AMES toxic0.6
CarcinogenicityNon-carcinogens0.9322
BiodegradationNot ready biodegradable0.7732
Rat acute toxicity3.0087 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.736
hERG inhibition (predictor II)Inhibitor0.8132
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Pfizer laboratories div pfizer inc
  • Roxane laboratories inc
  • Sigmapharm laboratories llc
  • Odyssey pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral5 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral10 mg
Prices
Unit descriptionCostUnit
Tofranil-PM 30 125 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 150 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 75 mg capsule Bottle588.33USD bottle
Tofranil 30 50 mg tablet Bottle185.09USD bottle
Tofranil-pm 100 mg capsule19.23USD capsule
Tofranil-pm 150 mg capsule18.86USD capsule
Tofranil-pm 75 mg capsule18.86USD capsule
Tofranil-pm 125 mg capsule18.68USD capsule
Anafranil 25 mg capsule13.51USD capsule
Anafranil 50 mg capsule13.51USD capsule
Anafranil 75 mg capsule13.24USD capsule
Tofranil 50 mg tablet6.64USD tablet
Norpramin 150 mg tablet6.23USD tablet
Surmontil 100 mg capsule5.92USD capsule
Tofranil 25 mg tablet4.97USD tablet
Tofranil 10 mg tablet4.73USD tablet
Norpramin 100 mg tablet4.27USD tablet
Surmontil 50 mg capsule4.15USD capsule
Vivactil 10 mg tablet4.05USD tablet
Norpramin 75 mg tablet3.27USD tablet
Protriptyline hcl 10 mg tablet3.07USD tablet
Vivactil 5 mg tablet2.86USD tablet
Norpramin 50 mg tablet2.59USD tablet
Surmontil 25 mg capsule2.49USD capsule
Protriptyline hcl 5 mg tablet2.12USD tablet
Norpramin 25 mg tablet1.4USD tablet
Norpramin 10 mg tablet1.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point169-171 °C (Protriptyline HCl)Not Available
water solubility1.04 mg/LNot Available
logP4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000231 mg/mLALOGPS
logP4.65ALOGPS
logP4.5ChemAxon
logS-6.1ALOGPS
pKa (Strongest Basic)10.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity87.3 m3·mol-1ChemAxon
Polarizability31.6 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-006x-8910000000-ec599ee02d998905757eView in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN06AA11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Protriptyline can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Protriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetamineProtriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineProtriptyline may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Protriptyline can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Protriptyline.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Protriptyline.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Protriptyline.
AbirateroneThe metabolism of Protriptyline can be decreased when combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Protriptyline.
AcenocoumarolProtriptyline may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Protriptyline.
AcetophenazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Protriptyline.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Protriptyline.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Protriptyline.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Protriptyline.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Protriptyline.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Protriptyline.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Protriptyline.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Protriptyline.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Protriptyline.
AlmotriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Almotriptan.
AlogliptinThe serum concentration of Protriptyline can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Protriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Protriptyline.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Protriptyline.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Protriptyline.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Protriptyline.
AmiodaroneProtriptyline may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Protriptyline can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Protriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Protriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Protriptyline.
AmoxapineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amperozide.
AmphetamineProtriptyline may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Protriptyline can be increased when it is combined with Amprenavir.
AnagrelideProtriptyline may increase the QTc-prolonging activities of Anagrelide.
Antithrombin III humanThe serum concentration of Protriptyline can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Protriptyline can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Protriptyline.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Protriptyline.
AprotininThe serum concentration of Protriptyline can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Arformoterol.
ArgatrobanThe serum concentration of Protriptyline can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Protriptyline.
ArtemetherProtriptyline may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Protriptyline can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Protriptyline.
AsenapineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Asenapine.
AsunaprevirThe serum concentration of Protriptyline can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Protriptyline can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Protriptyline.
AtomoxetineThe metabolism of Protriptyline can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Protriptyline.
AzaperoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Azaperone.
AzelastineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Protriptyline.
AzithromycinProtriptyline may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Protriptyline.
BambuterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Protriptyline.
BatimastatThe serum concentration of Protriptyline can be increased when it is combined with Batimastat.
BedaquilineProtriptyline may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilThe serum concentration of Protriptyline can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the serotonergic activities of Protriptyline.
BenzamidineThe serum concentration of Protriptyline can be increased when it is combined with Benzamidine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Protriptyline.
BenzphetamineProtriptyline may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Protriptyline.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Protriptyline.
BetaxololThe metabolism of Protriptyline can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Protriptyline.
BifeprunoxThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bifeprunox.
BivalirudinThe serum concentration of Protriptyline can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Protriptyline can be increased when it is combined with Boceprevir.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Protriptyline.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Protriptyline.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Protriptyline.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Protriptyline.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Protriptyline.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Protriptyline.
BrompheniramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Protriptyline.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Protriptyline.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Protriptyline.
BupropionThe metabolism of Protriptyline can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Protriptyline.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Protriptyline.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Protriptyline.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Protriptyline.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Protriptyline.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Protriptyline.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Protriptyline.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Protriptyline.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Protriptyline.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Protriptyline.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Protriptyline.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Protriptyline.
CandoxatrilThe serum concentration of Protriptyline can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Protriptyline can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Protriptyline can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Protriptyline.
CarbinoxamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Protriptyline.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Protriptyline.
CariprazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carisoprodol.
CaroxazoneCaroxazone may increase the serotonergic activities of Protriptyline.
CelecoxibThe metabolism of Protriptyline can be decreased when combined with Celecoxib.
CeliprololThe risk or severity of adverse effects can be increased when Protriptyline is combined with Celiprolol.
CeritinibProtriptyline may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Protriptyline.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Protriptyline.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Protriptyline.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Protriptyline.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Protriptyline.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Protriptyline.
ChloroquineProtriptyline may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Protriptyline can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorphenamine.
ChlorphentermineProtriptyline may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Protriptyline can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Protriptyline can be decreased when combined with Cholecalciferol.
ChymostatinThe serum concentration of Protriptyline can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Protriptyline can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Protriptyline can be increased when it is combined with Cilazapril.
CimetidineThe metabolism of Protriptyline can be decreased when combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Protriptyline.
CinacalcetThe serum concentration of Protriptyline can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Protriptyline.
CiprofloxacinProtriptyline may increase the QTc-prolonging activities of Ciprofloxacin.
CirazolineProtriptyline may increase the vasopressor activities of Cirazoline.
CisaprideProtriptyline may increase the arrhythmogenic activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Protriptyline.
CitalopramThe risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram.
CitalopramThe metabolism of Protriptyline can be decreased when combined with Citalopram.
ClarithromycinProtriptyline may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Protriptyline can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clenbuterol.
ClidiniumThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Protriptyline.
ClobazamThe metabolism of Protriptyline can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Protriptyline.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Protriptyline.
ClomipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clomipramine.
ClomipramineThe metabolism of Protriptyline can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clonazepam.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Protriptyline.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Protriptyline.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Protriptyline.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Protriptyline.
ClotrimazoleThe metabolism of Protriptyline can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clozapine.
ClozapineThe metabolism of Protriptyline can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Protriptyline can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Protriptyline.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Protriptyline.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Protriptyline.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Protriptyline.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Protriptyline.
CrizotinibProtriptyline may increase the QTc-prolonging activities of Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Protriptyline.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Protriptyline.
CyproheptadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Protriptyline can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Protriptyline.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Protriptyline.
DantroleneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Protriptyline.
DapiprazoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Protriptyline.
DarifenacinThe metabolism of Protriptyline can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Protriptyline can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Protriptyline.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Protriptyline.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Protriptyline.
DelavirdineThe metabolism of Protriptyline can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Protriptyline.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Protriptyline.
DesipramineThe metabolism of Protriptyline can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Protriptyline.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Protriptyline.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Protriptyline.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Protriptyline.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Protriptyline.
DextroamphetamineProtriptyline may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Protriptyline.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Protriptyline.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Protriptyline.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Protriptyline.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Protriptyline.
DicoumarolProtriptyline may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Protriptyline.
DifenoxinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Protriptyline.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Protriptyline.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Protriptyline.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Protriptyline.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Protriptyline.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Protriptyline.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Protriptyline.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Protriptyline.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Protriptyline.
DimenhydrinateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Protriptyline can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Protriptyline.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Protriptyline.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Protriptyline.
DisopyramideProtriptyline may increase the QTc-prolonging activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dobutamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Protriptyline.
DofetilideProtriptyline may increase the QTc-prolonging activities of Dofetilide.
DolasetronProtriptyline may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Protriptyline.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Protriptyline.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Protriptyline.
DoxepinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Protriptyline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
DoxylamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Protriptyline.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
DronedaroneProtriptyline may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Protriptyline can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Protriptyline.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Protriptyline.
DuloxetineThe metabolism of Protriptyline can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Protriptyline.
EcabetThe serum concentration of Protriptyline can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Protriptyline.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Protriptyline.
EdoxabanThe serum concentration of Protriptyline can be increased when it is combined with Edoxaban.
EfavirenzThe risk or severity of adverse effects can be increased when Protriptyline is combined with Efavirenz.
ElafinThe serum concentration of Protriptyline can be increased when it is combined with Elafin.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Protriptyline.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Protriptyline.
EliglustatProtriptyline may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Protriptyline can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Protriptyline can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Protriptyline can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Protriptyline can be increased when it is combined with Enalkiren.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Protriptyline.
EntacaponeThe risk or severity of adverse effects can be increased when Protriptyline is combined with Entacapone.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Protriptyline.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Protriptyline.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Protriptyline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergonovine.
ErgotamineProtriptyline may increase the vasopressor activities of Ergotamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Protriptyline.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Protriptyline.
ErythromycinProtriptyline may increase the QTc-prolonging activities of Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Protriptyline.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Protriptyline.
EstriolThe serum concentration of Estriol can be increased when it is combined with Protriptyline.
EstroneThe serum concentration of Estrone can be increased when it is combined with Protriptyline.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Protriptyline.
EthanolProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Protriptyline.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Protriptyline.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Protriptyline.
EthosuximideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethotoin.
Ethyl biscoumacetateProtriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Protriptyline.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Protriptyline.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Protriptyline.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Protriptyline.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Protriptyline.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Protriptyline.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Protriptyline.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Protriptyline.
EtoperidoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Protriptyline.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Protriptyline.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Protriptyline.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Protriptyline.
EzogabineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fenfluramine.
FenoterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Protriptyline.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Protriptyline.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Protriptyline.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Protriptyline.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Protriptyline.
FlecainideProtriptyline may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Protriptyline.
FlunarizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Protriptyline.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Protriptyline.
FlupentixolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Protriptyline.
FluspirileneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Protriptyline.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluvoxamine.
FluvoxamineThe metabolism of Protriptyline can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Formoterol.
FosamprenavirThe serum concentration of Protriptyline can be increased when it is combined with Fosamprenavir.
FosinoprilThe serum concentration of Protriptyline can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Protriptyline.
FrovatriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Protriptyline.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Protriptyline.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Protriptyline is combined with gabapentin enacarbil.
Gadobenic acidProtriptyline may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Protriptyline.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Protriptyline.
GeldanamycinThe serum concentration of Protriptyline can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Protriptyline.
GemifloxacinProtriptyline may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Protriptyline.
GM6001The serum concentration of Protriptyline can be increased when it is combined with GM6001.
GoserelinProtriptyline may increase the QTc-prolonging activities of Goserelin.
GranisetronProtriptyline may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Protriptyline.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Protriptyline.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Protriptyline.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Protriptyline.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Protriptyline.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Protriptyline.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Protriptyline.
HaloperidolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Haloperidol.
HaloperidolThe metabolism of Protriptyline can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Protriptyline.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Protriptyline.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Protriptyline.
HirulogThe serum concentration of Protriptyline can be increased when it is combined with Hirulog.
HydracarbazineHydracarbazine may increase the serotonergic activities of Protriptyline.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Protriptyline.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Protriptyline.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline.
Hydroxyamphetamine hydrobromideProtriptyline may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
HydroxyzineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Protriptyline.
IbutilideProtriptyline may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Protriptyline.
IloperidoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Protriptyline.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Protriptyline.
ImipramineThe metabolism of Protriptyline can be decreased when combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indalpine.
IndinavirThe serum concentration of Protriptyline can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Protriptyline.
IproclozideIproclozide may increase the serotonergic activities of Protriptyline.
IproniazidIproniazid may increase the serotonergic activities of Protriptyline.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Protriptyline.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Protriptyline.
IsocarboxazidThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Protriptyline.
IsoflurophateThe serum concentration of Protriptyline can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Protriptyline can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isoprenaline.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Protriptyline.
IxazomibThe serum concentration of Protriptyline can be increased when it is combined with Ixazomib.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Protriptyline.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Protriptyline.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Protriptyline.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Protriptyline.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Protriptyline.
KetoconazoleThe metabolism of Protriptyline can be decreased when combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Protriptyline.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Protriptyline.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Protriptyline.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Protriptyline.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Protriptyline.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Protriptyline.
LenvatinibProtriptyline may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Protriptyline can be increased when it is combined with Lepirudin.
LeuprolideProtriptyline may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Protriptyline.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Protriptyline.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Protriptyline.
LevocabastineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levodopa.
LevofloxacinProtriptyline may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Protriptyline.
LevomilnacipranThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Protriptyline.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Protriptyline.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Protriptyline.
LinagliptinThe serum concentration of Protriptyline can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Protriptyline.
LinezolidThe risk or severity of adverse effects can be increased when Protriptyline is combined with Linezolid.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Protriptyline.
LiotrixLiotrix may increase the arrhythmogenic activities of Protriptyline.
LisdexamfetamineProtriptyline may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Protriptyline can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Protriptyline.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Protriptyline.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Protriptyline.
LopinavirThe serum concentration of Protriptyline can be increased when it is combined with Lopinavir.
LopinavirProtriptyline may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Protriptyline.
LorcaserinThe metabolism of Protriptyline can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Protriptyline.
LoxapineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Protriptyline is combined with Lu AA21004.
LumefantrineProtriptyline may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Protriptyline can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Protriptyline.
MaprotilineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Maprotiline.
MebanazineMebanazine may increase the serotonergic activities of Protriptyline.
MeclizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Protriptyline.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Protriptyline.
MelperoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Melperone.
MephentermineProtriptyline may increase the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Protriptyline.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline.
MesoridazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Mesoridazine.
MetaraminolProtriptyline may increase the vasopressor activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Metaxalone.
MethadoneProtriptyline may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Protriptyline can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Protriptyline.
MethamphetamineProtriptyline may increase the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Protriptyline.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Protriptyline.
MethocarbamolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Protriptyline.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Protriptyline.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methotrimeprazine.
MethoxamineProtriptyline may increase the vasopressor activities of Methoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Protriptyline.
MethsuximideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.
Methylene blueProtriptyline may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Protriptyline.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Protriptyline.
MetoclopramideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Protriptyline.
MetoprololThe metabolism of Protriptyline can be decreased when combined with Metoprolol.
MetyrosineProtriptyline may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Protriptyline.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Protriptyline.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Protriptyline.
MidodrineProtriptyline may increase the vasopressor activities of Midodrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Protriptyline.
MilnacipranThe risk or severity of adverse effects can be increased when Protriptyline is combined with Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Protriptyline.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Protriptyline.
MirabegronThe metabolism of Protriptyline can be decreased when combined with Mirabegron.
MirtazapineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Protriptyline.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Protriptyline.
MoclobemideMoclobemide may increase the serotonergic activities of Protriptyline.
MoclobemideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Moclobemide.
MoexiprilThe serum concentration of Protriptyline can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Protriptyline.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Protriptyline.
MoxifloxacinProtriptyline may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Protriptyline.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Protriptyline.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Protriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.
NabiloneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Protriptyline.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Protriptyline.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Protriptyline.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Protriptyline.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Protriptyline.
NaratriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Naratriptan.
NCX 4016The serum concentration of Protriptyline can be increased when it is combined with NCX 4016.
NefazodoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nefazodone.
NelfinavirThe serum concentration of Protriptyline can be increased when it is combined with Nelfinavir.
NevirapineThe metabolism of Protriptyline can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Protriptyline.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Protriptyline.
NicardipineThe metabolism of Protriptyline can be decreased when combined with Nicardipine.
NicorandilProtriptyline may increase the hypotensive activities of Nicorandil.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Protriptyline.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Protriptyline.
NilotinibThe metabolism of Protriptyline can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Protriptyline.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Protriptyline.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Protriptyline.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Protriptyline.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Protriptyline.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Protriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nortriptyline.
OctamoxinOctamoxin may increase the serotonergic activities of Protriptyline.
OfloxacinProtriptyline may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olanzapine.
OlodaterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olopatadine.
OmapatrilatThe serum concentration of Protriptyline can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Protriptyline.
OndansetronThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Protriptyline.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Protriptyline.
OrciprenalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Orciprenaline.
OrphenadrineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Protriptyline.
OsanetantThe risk or severity of adverse effects can be increased when Protriptyline is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Protriptyline.
OtamixabanThe serum concentration of Protriptyline can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Protriptyline.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Protriptyline.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Protriptyline.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Protriptyline.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Protriptyline.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Protriptyline.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Protriptyline.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Protriptyline.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Protriptyline.
PalonosetronPalonosetron may increase the serotonergic activities of Protriptyline.
PanobinostatProtriptyline may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Protriptyline can be decreased when combined with Panobinostat.
ParaldehydeProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Protriptyline.
PargylinePargyline may increase the serotonergic activities of Protriptyline.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Protriptyline.
Peginterferon alfa-2bThe serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineProtriptyline may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Protriptyline.
PerampanelThe risk or severity of adverse effects can be increased when Protriptyline is combined with Perampanel.
PerflutrenProtriptyline may increase the QTc-prolonging activities of Perflutren.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Protriptyline.
PerindoprilThe serum concentration of Protriptyline can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Protriptyline is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Protriptyline.
PhenelzinePhenelzine may increase the serotonergic activities of Protriptyline.
PhenelzineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Phenelzine.
PhenindioneProtriptyline may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Protriptyline.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Protriptyline.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Protriptyline.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Protriptyline.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Protriptyline.
PhenprocoumonProtriptyline may increase the anticoagulant activities of Phenprocoumon.
PhentermineProtriptyline may increase the stimulatory activities of Phentermine.
PhenylephrineProtriptyline may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Protriptyline.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Protriptyline.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Protriptyline.
PhosphoramidonThe serum concentration of Protriptyline can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pirbuterol.
PirlindolePirlindole may increase the serotonergic activities of Protriptyline.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Protriptyline.
PivhydrazinePivhydrazine may increase the serotonergic activities of Protriptyline.
PizotifenThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Protriptyline.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Protriptyline.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Protriptyline.
PramipexoleProtriptyline may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Protriptyline.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Protriptyline.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Protriptyline.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Protriptyline.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Protriptyline.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Protriptyline.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Protriptyline.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Protriptyline.
PrimaquineProtriptyline may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Primidone.
PrinomastatThe serum concentration of Protriptyline can be increased when it is combined with Prinomastat.
ProcainamideProtriptyline may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Protriptyline.
ProcarbazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Protriptyline.
PromazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Promazine.
PromazineThe metabolism of Protriptyline can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Promethazine.
PropafenoneProtriptyline may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Protriptyline.
PropericiazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Protriptyline.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Protriptyline.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Protriptyline.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Protriptyline.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Protriptyline.
QuetiapineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Quetiapine.
QuinaprilThe serum concentration of Protriptyline can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Protriptyline.
QuinidineThe metabolism of Protriptyline can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Protriptyline.
QuinineThe metabolism of Protriptyline can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ramelteon.
RamiprilThe serum concentration of Protriptyline can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Protriptyline.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Protriptyline.
RanolazineThe metabolism of Protriptyline can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Protriptyline.
RasagilineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Protriptyline.
RemikirenThe serum concentration of Protriptyline can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Reserpine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Protriptyline.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Protriptyline.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Protriptyline.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Protriptyline.
RitodrineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ritodrine.
RitonavirThe serum concentration of Protriptyline can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Protriptyline can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Rizatriptan.
RolapitantThe metabolism of Protriptyline can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Protriptyline.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Protriptyline.
RopiniroleProtriptyline may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Protriptyline can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Protriptyline.
RotigotineProtriptyline may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Protriptyline.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Protriptyline.
SafrazineSafrazine may increase the serotonergic activities of Protriptyline.
SalbutamolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Salbutamol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Protriptyline.
SalmeterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Salmeterol.
SaquinavirThe serum concentration of Protriptyline can be increased when it is combined with Saquinavir.
SaquinavirProtriptyline may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Protriptyline can be increased when it is combined with Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Protriptyline.
SelegilineSelegiline may increase the serotonergic activities of Protriptyline.
SelegilineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Protriptyline.
SertindoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sertraline.
SertralineThe metabolism of Protriptyline can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Protriptyline.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Protriptyline.
SimeprevirThe serum concentration of Protriptyline can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Protriptyline can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Protriptyline.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Protriptyline.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Protriptyline.
SotalolProtriptyline may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Protriptyline.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Protriptyline.
SpiraprilThe serum concentration of Protriptyline can be increased when it is combined with Spirapril.
St. John's WortThe metabolism of Protriptyline can be increased when combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline.
SulfisoxazoleProtriptyline may increase the QTc-prolonging activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sumatriptan.
SuvorexantThe risk or severity of adverse effects can be increased when Protriptyline is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Protriptyline.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Protriptyline.
TapentadolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Protriptyline.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Protriptyline.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Protriptyline.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Protriptyline can be increased when it is combined with Telaprevir.
TelavancinProtriptyline may increase the QTc-prolonging activities of Telavancin.
TelithromycinProtriptyline may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Protriptyline.
TemocaprilThe serum concentration of Protriptyline can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Protriptyline.
TerbinafineThe metabolism of Protriptyline can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Terbutaline.
TetrabenazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Protriptyline.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Protriptyline.
ThalidomideProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Protriptyline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Protriptyline.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Protriptyline.
ThioproperazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thioridazine.
ThiorphanThe serum concentration of Protriptyline can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thiothixene.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Protriptyline.
TiagabineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Protriptyline.
TiclopidineThe metabolism of Protriptyline can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Protriptyline.
TimololThe serum concentration of Timolol can be increased when it is combined with Protriptyline.
TipranavirThe serum concentration of Protriptyline can be increased when it is combined with Tipranavir.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Protriptyline.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Protriptyline.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Protriptyline.
ToloxatoneToloxatone may increase the serotonergic activities of Protriptyline.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Protriptyline.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Protriptyline.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Protriptyline.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Protriptyline.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Protriptyline.
TrandolaprilThe serum concentration of Protriptyline can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Protriptyline.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Protriptyline.
TranylcypromineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Protriptyline.
TrazodoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Protriptyline.
TrifluoperazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Triprolidine.
UbenimexThe serum concentration of Protriptyline can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Protriptyline.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Protriptyline.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Protriptyline.
VandetanibProtriptyline may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Protriptyline.
VemurafenibProtriptyline may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Protriptyline.
VenlafaxineThe metabolism of Protriptyline can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Protriptyline.
VigabatrinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vigabatrin.
VilanterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vilazodone.
VildagliptinThe serum concentration of Protriptyline can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Protriptyline.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Protriptyline.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Protriptyline.
VortioxetineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vortioxetine.
WarfarinProtriptyline may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Protriptyline can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Protriptyline.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Protriptyline.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Protriptyline.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Protriptyline.
ZiconotideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Protriptyline.
ZimelidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ziprasidone.
ZiprasidoneThe metabolism of Protriptyline can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Protriptyline.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Protriptyline.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Protriptyline.
ZonisamideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Protriptyline.
ZotepineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  4. Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ: [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology. 1996 Jan;35(1):63-70. [PubMed:8684598 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. McDougle CJ, Epperson CN, Price LH, Gelernter J: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998 May;3(3):270-3. [PubMed:9672904 ]
  2. Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: [Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population]. Encephale. 1996 May;22 Spec No 1:39-48. [PubMed:8767026 ]
  3. Frazer A, Daws LC: Serotonin transporter function in vivo: assessment by chronoamperometry. Ann N Y Acad Sci. 1998 Dec 15;861:217-29. [PubMed:9928259 ]
  4. Daws LC, Toney GM, Gerhardt GA, Frazer A: In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters. J Pharmacol Exp Ther. 1998 Aug;286(2):967-76. [PubMed:9694957 ]
  5. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  6. Kovachich GB, Aronson CE, Brunswick DJ: Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 1992 Dec;7(4):317-24. [PubMed:1476595 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23